Print

UK's NICE Rejects GlaxoSmithKline (GSK)'s Revolade For Blood Condition  
10/27/2010 7:50:15 AM

LONDON (Dow Jones)--The U.K.'s healthcare costs watchdog Wednesday said GlaxoSmithKline PLC's (GSK.LN) Revolade isn't recommended for use on the state-funded National Health Service to treat patients having a rare blood condition.
//-->